Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics is a clinical-stage biopharmaceutical company that has recently achieved European commercial launch of its product LYTENAVA (bevacizumab gamma) for the treatment of wet AMD in U.K. and Germany and plans to launch in Switzerland in 2027. While the company has reported revenue of $(1) million in Q1 of FY26, it is expected to grow significantly with its product launch. However, risks to share price target include balance sheet and liquidity risks, failure to obtain regulatory approvals and suitable reimbursement, and competition in the eye disease therapy space.

Bears say

Outlook Therapeutics is a clinical-stage biopharmaceutical company with only one main candidate, ONS-5010, currently in development for the treatment of wet age-related macular degeneration (wet AMD) and other eye diseases. However, the company has faced challenges with FDA approval for its product and may need to conduct further studies, which could require additional capital and result in share dilution for shareholders. Additionally, Outlook faces competition from well-established companies in the eye disease therapy space, potentially limiting their market potential. All of these factors contribute to a negative outlook for the company's future financial performance.

OTLK has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 3 analysts, OTLK has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.